Fibronectin Or Derivative Patents (Class 514/9.3)
-
Patent number: 11999972Abstract: Stem cells can be efficiently proliferated by culturing the stem cells in the presence of a novel recombinant fibronectin fragment.Type: GrantFiled: July 28, 2017Date of Patent: June 4, 2024Assignee: TAKARA BIO INC.Inventors: Tomomi Otsuji, Toshikazu Nishie, Risa Kato, Sachiko Okamoto, Tatsuji Enoki, Junichi Mineno
-
Patent number: 11584918Abstract: The present disclosure relates generally to methods and compositions for transferring a genetic circuit from one prokaryotic cell (“donor cell”) to another prokaryotic cell (“recipient cell” or “target cell” which are used interchangeably herein). More specifically, the present disclosure relates to prokaryotic donor cells comprising (i) a genetic circuit of interest and (ii) one or more expressed transcriptional repressor proteins and the use of said donor cells in the efficient transfer of the genetic circuit into a prokaryotic recipient cell. The genetic circuit includes nucleic acid sequences encoding a RNA molecule or protein of interest.Type: GrantFiled: March 16, 2020Date of Patent: February 21, 2023Assignee: ELIGO BIOSCIENCEInventors: Jesus Fernandez Rodriguez, Antonina Krawczyk, Xavier Duportet
-
Patent number: 11111273Abstract: There is described herein, multimers comprising a plurality of compounds covalently linked together, the compounds independently being of formula (I).Type: GrantFiled: November 10, 2017Date of Patent: September 7, 2021Assignee: Zealand Pharma A/SInventors: Mohammed Monzur Morshed, Sai Kumar Chakka, Jennifer L. Hickey, Manuel Perez Vazquez, Andrew Roughton, Adam Paul Kafal, Narendrakumar B. Patel
-
Patent number: 11065265Abstract: The present application and its embodiments teach stable compositions of fosaprepitant or a pharmaceutically acceptable salt thereof with such compositions lacking polysorbate 80 and containing dual functional excipients of hydrolysis inhibition and solubility enhancement. Further described are methods of preparation of such compositions. Among other advantages of contemplated compositions, fosaprepitant hydrolysis degradation is kept low and the compositions maintain physically and chemically stable for prolonged period.Type: GrantFiled: January 11, 2019Date of Patent: July 20, 2021Assignee: SPES PHARMACEUTICALS INC.Inventors: Jianwei Yu, Yulu Wang
-
Patent number: 10940233Abstract: Provided is a method of forming a fibrinogen hydrogel composition, the method including providing a fibrinogen hydrogel or precursor thereof, comprising fibrinogen hydrogel forming salt. The fibrinogen hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrinogen hydrogel. The method further includes denaturing the fibrinogen hydrogel such as by heating. The method optionally further includes combining the fibrinogen hydrogel with a carrier material. When present, the concentration of the carrier material typically ranges from 0.1 to about 50 wt.-%. The method further includes reducing the salt concentration below the threshold concentration to form a fibrinogen hydrogel.Type: GrantFiled: October 4, 2017Date of Patent: March 9, 2021Assignee: 3M Innovative Properties CompanyInventors: James P. Dizio, Zhicheng Tian, Jason W. Bjork, Amy S. Determan, Robert A. Asmus, Jonathan J. O'Hare
-
Patent number: 10787499Abstract: Certain embodiments of the invention provide epithelial cell adhesion molecule (EpCAM) binding polypeptides, as well as conjugates and CSANs comprising such polypeptides. Additionally, certain embodiments of the invention also provide methods of using such polypeptides and compounds for molecular imaging and molecularly targeted therapies.Type: GrantFiled: February 13, 2018Date of Patent: September 29, 2020Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Benjamin Hackel, Carston R. Wagner, Lawrence A. Stern, Clifford Csizmar
-
Patent number: 10738102Abstract: The present disclosure provides pharmaceutical compositions comprising fibronectin based scaffold domain proteins that bind, for example, proprotein convertase subtilisin kexin-9 (PCSK9).Type: GrantFiled: September 20, 2019Date of Patent: August 11, 2020Assignee: LIB THERAPEUTICS, LLC.Inventors: Tracy S. Mitchell, Richard Mealey
-
Patent number: 10472422Abstract: Provided herein are tetravalent antibodies that specifically bind to human PSGL-1. Unlike bivalent antibodies, these tetravalent antibodies contain a dimer of two monomers, with each monomer comprising two light chain variable (VL) domains and two heavy chain variable (VH) domains. This format allows for cross-linker/FcR-expressing cell-independent tetravalent antibodies against PSGL-1 that show enhanced efficacy as compared to bivalent PSGL-1 antibodies. These tetravalent antibodies can be used in a variety of diagnostic and therapeutic methods, including without limitation treating T-cell mediated inflammatory diseases, transplantations, and transfusions.Type: GrantFiled: January 6, 2017Date of Patent: November 12, 2019Assignees: ABGENOMICS INTERNATIONAL INC., BIOALLIANCE C.V.Inventors: Rong-Hwa Lin, Shih-Yao Lin, Yu-Ying Tsai
-
Patent number: 10450363Abstract: Provided herein are proteins comprising a fibronectin based scaffold (FBS) domain, e.g., 10Fn3 molecules, that bind specifically to a target, and wherein the FBS domain is linked at its C-terminus to a region consisting of PmXn, wherein P is proline, X is any amino acid and wherein n is 0 or an integer that is at least 1 and m is an integer that is at least 1, and wherein the PmXn moiety provides an enhanced property to the FBS domain, e.g., enhanced stability, relative to the protein that is not linked to the PmXn moiety.Type: GrantFiled: March 19, 2015Date of Patent: October 22, 2019Assignee: BRISTOL-MYERS SQUIBB COMPANYInventor: Dasa Lipovsek
-
Patent number: 10245328Abstract: The present disclosure relates to a magnetic resonance imaging (MRI) contrast agent containing a gadolinium complex, and more specically, to a DO3A-tranexamic acid compound having a structure of a chemical formula 1, or an ester compound thereof, and gadolinium complexes thereof. The DO3A-tranexamic acid compound or the ester compound thereof may be used to prepare gadolinium complexes. The gadolinium complexes exhibit thermodynamic and kinetic stabilities, and show the relaxation rate equal to that of the clinical contrast agent which is currently commercially available. Therefore, the gadolinium complexes can be widely used as an MRI contrast agent.Type: GrantFiled: January 8, 2015Date of Patent: April 2, 2019Assignee: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Tae-Jeong Kim, Yong Min Chang
-
Patent number: 10016452Abstract: A formulation for reducing corneal scarring and related eye conditions, is disclosed. The formulation comprises an effective amount of fibromodulin and can be administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye.Type: GrantFiled: May 1, 2009Date of Patent: July 10, 2018Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Chia Soo
-
Patent number: 9017655Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.Type: GrantFiled: December 3, 2012Date of Patent: April 28, 2015Assignee: Bristol-Myers Squibb CompanyInventors: Stuart Emanuel, Linda Engle, Ray Camphausen, Martin C. Wright, Ginger Chao Rakestraw, Marco Gottardis, Joan Carboni
-
Publication number: 20150111822Abstract: There are provided compositions and methods for modulating stem cell division, in particular, division symmetry. It has been demonstrated that Wnt7a polypeptide fragments promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro, ex vivo, and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.Type: ApplicationFiled: September 14, 2012Publication date: April 23, 2015Inventors: Michael A. Rudnicki, Conrad Florian Bentzinger, Radoslav Zinoviev
-
Publication number: 20150051149Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.Type: ApplicationFiled: October 31, 2012Publication date: February 19, 2015Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Jonathan Davis, Dasa Lipovsek, Ray Camphausen
-
Publication number: 20150030580Abstract: The present invention relates to biodegradable scaffolds composed of a naturally-occurring protein backbone cross-linked by a synthetic polymer. Specifically, the present invention provides PEGylated-fibrinogen scaffold and methods of generating and using same for treating disorders requiring tissue regeneration.Type: ApplicationFiled: October 13, 2014Publication date: January 29, 2015Inventors: DROR SELIKTAR, LIORA ALMANY
-
Publication number: 20150004138Abstract: The invention provides a genipin cross-linked fibrin gel. The ratio of genipin to fibrin in the gel ranges from about 0.1:1 to about 10:1 (genipin:fibrin). The gel can be hydrogel. The gel further contains proteins from the extracellular matrix that promote cell growth and density in and around the gel. Also provided is method for repairing tissue defects by administering the gel to site of tissue defect.Type: ApplicationFiled: September 11, 2014Publication date: January 1, 2015Inventors: James C. Iatridis, Clare Canal Guterl
-
Patent number: 8921317Abstract: A fibrin-based hemostatic agent suitable for both civilian and military use is disclosed. The hemostatic agent comprises (i) nanoparticles to which a plurality of Knob-A recognition sequences are attached, and (ii) coiled-coils of recombinantly-produced human fibrinogen ? and chains and the ? chain globular domain. A delivery system for the hemostatic agent also is disclosed, which additionally comprises means for delivering (i) and (ii) to a wound site. The delivery means may be a CO2 canister or a shaker jet.Type: GrantFiled: June 11, 2010Date of Patent: December 30, 2014Assignee: BAE Systems Information and Electronic Systems Integration Inc.Inventor: Robert A. Burton
-
Publication number: 20140271610Abstract: The present invention relates to composition(s) comprising collagen, calcium ions and alginate, wherein the composition polymerizes in situ when contacted with blood. The composition may further comprise an erythrocyte aggregation agent and/or a platelet activation agent. The composition may be formulated into two separate formulations. The first formulation comprises collagen in a calcium-containing solution and a second formulation comprises an aqueous alginate solution. The two formulations can be mixed prior to the contact with blood or mixed coincident with the contact with blood.Type: ApplicationFiled: March 12, 2013Publication date: September 18, 2014Applicant: ORTHOVITA, INC.Inventor: James San Antonio
-
Patent number: 8835501Abstract: This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.Type: GrantFiled: May 11, 2006Date of Patent: September 16, 2014Assignee: TopoTarget UK LimitedInventors: Richard J. Bastin, Nicholas J. Hughes
-
Publication number: 20140186369Abstract: The invention provides a method of inhibiting neovascularization in a subject. The method comprises administering to the subject an agent that interferes with fibronectin (Fn) matrix assembly in an amount effective to inhibit neovascularization. The invention also provides a method of identifying an agent that inhibits neovascularization. The method comprises detecting fibronectin (Fn) matrix assembly by stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent. A decrease in Fn matrix assembly in the presence of the agent compared to Fn matrix assembly in the absence of the agent is indicative of an agent that inhibits neovascularization. Alternatively, the method of identifying an agent that inhibits neovascularization comprises detecting changes in nuclear architecture in stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent.Type: ApplicationFiled: February 28, 2014Publication date: July 3, 2014Applicant: The Regents of The University of MichiganInventors: Stephen J. Weiss, Robert G. Rowe
-
Publication number: 20140187488Abstract: Described herein are methods for maintaining PEGylation and inhibiting dePEGylation of polypeptides, such as fibronectin-based scaffold proteins, during storage.Type: ApplicationFiled: May 15, 2012Publication date: July 3, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Bernice Yeung, Jack Wang
-
Patent number: 8728483Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: GrantFiled: June 26, 2012Date of Patent: May 20, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Ray Camphausen, Eric Furfine, Irvith M. Carvajal, H. Nicholas Marsh, Marco Gottardis, Joan Carboni, Ricardo Attar
-
Publication number: 20140107020Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: ApplicationFiled: September 12, 2013Publication date: April 17, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO
-
Patent number: 8697048Abstract: The present invention relates to the use of self-assembling peptide amphiphiles to prevent tumor formation by transplanted stem cells. The present invention further relates to the use of self-assembling peptide amphiphiles to treat cancers.Type: GrantFiled: December 21, 2011Date of Patent: April 15, 2014Assignee: Northwestern UniversityInventors: Li-Ru Zhao, John A. Kessler
-
Publication number: 20140038893Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: ApplicationFiled: August 1, 2013Publication date: February 6, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Ray CAMPHAUSEN, Brent MORSE, Stuart EMANUEL, David FABRIZIO
-
Publication number: 20140004158Abstract: Cell attachment coatings for articles such as implantable medical devices and cell culture vessels are disclosed. The coatings include an intermediate coater layer which includes a phosphorous-containing component that is bonded in the coating by reacted photoreactive functional groups. The coating also include a second coated layer including an immobilized ECM protein or peptide that includes an active portion of an ECM protein that is able to serve as an outer layer to contact cells during use. The coatings promoted enhanced cell binding and growth.Type: ApplicationFiled: June 28, 2013Publication date: January 2, 2014Inventor: Joseph S. McGonigle
-
Patent number: 8609613Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.Type: GrantFiled: July 18, 2012Date of Patent: December 17, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
-
Publication number: 20130315889Abstract: The present invention relates to protein complexes or scaffold comprising cartilage oligomeric matrix protein (COMP) polypeptides bound to one or more growth factors, and methods of their use in promoting chondrogenesis and/or osteogenesis, and repair of cartilage and bone lesions.Type: ApplicationFiled: September 14, 2011Publication date: November 28, 2013Applicant: The Regents of the University of CaliforniaInventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik
-
Patent number: 8591885Abstract: Biocompatible intraocular drug delivery systems include a carbonic anhydrase inhibitor therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.Type: GrantFiled: October 31, 2007Date of Patent: November 26, 2013Assignee: Allergan, Inc.Inventors: James N. Chang, Patrick M. Hughes, Gerald W. Devries
-
Publication number: 20130295081Abstract: The presently-disclosed subject matter includes polyurethane composites that include tissue component(s), as well as methods of making such composites and uses thereof. The polyurethane component can comprise a polyisocyanate prepolymer and a polyol. The tissue component can be a polysaccharide. Exemplary composites can be moldable and/or injectable, and can cure into a porous composite that provides mechanical strength and/or supports the in-growth of cells. Inventive composites have the advantage of being able to fill irregularly shaped areas, voids, or the like. Exemplary composites can be used for treating wounds.Type: ApplicationFiled: April 16, 2013Publication date: November 7, 2013Inventors: Scott A. Guelcher, Andrea Hafeman, Jeffrey Davidson, Lillian M. Nanney, Elizabeth Adolph
-
Patent number: 8569227Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof, exhibit enhanced thermal and chemical stability while presenting six modifiable loop domains which can be engineered to form a binding partner capable of binding to a target for applications in diagnostic and/or therapeutic compositions, methods and devices.Type: GrantFiled: April 29, 2011Date of Patent: October 29, 2013Assignee: Janssen Biotech, Inc.Inventor: Steven Jacobs
-
Patent number: 8524244Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: GrantFiled: February 10, 2009Date of Patent: September 3, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Ray Camphausen, Brent Morse, Stuart Emanuel, David Fabrizio
-
Publication number: 20130217625Abstract: Disclosed is a composition of matter involving a recombinant fusion protein comprising a a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10th fibronectin III domain, a SH3 domain, a SH2 domain, a CH2 domain of IgG1, a PDZ domain, a thrombospondin repeat domain, an ubiquitin domain, a leucine-rich repeat domain, a villin headpiece HP35 domain, a villin headpiece HP76 domain, or a fragment or modification of any of these. Also disclosed are nucleic acids (e.g., DNA constructs) encoding the fusion protein, expression vectors and recombinant host cells for expression of the fusion protein, and pharmaceutical compositions containing the recombinant fusion protein and a pharmaceutically acceptable carrier, and method of producing a pharmacologically active recombinant fusion protein.Type: ApplicationFiled: April 11, 2013Publication date: August 22, 2013Applicant: Amgen Inc.Inventor: Amgen Inc.
-
Publication number: 20130216604Abstract: A polypeptide for inhibiting, treating or diagnosing metastasis and an use thereof are disclosed, wherein the polypeptide is a polypeptide, a derivative polypeptide, or a mutated polypeptide of a fibronectin-binding domain of dipeptidyl peptidase IV. In addition, a pharmaceutical composition treating or diagnosing metastasis is also disclosed, which comprises the aforementioned polypeptide, and a pharmaceutically acceptable carrier.Type: ApplicationFiled: August 23, 2012Publication date: August 22, 2013Applicant: National Cheng Kung UniversityInventors: Hung-Chi Chen, Chien-Sheng Chen, Yu-Chuan Lin, Chin-Yun Cheng
-
Publication number: 20130190224Abstract: The present invention is directed to various uses of fibronectin binding proteins or polypeptides for treating and preventing fibrosis and fibrosis related conditions. The fibronectin binding proteins and polypeptides are also useful for treating conditions associated with vascular remodeling and cardiac dysfunction.Type: ApplicationFiled: February 3, 2011Publication date: July 25, 2013Applicants: MAX-PLANCK-GESELLSCHAFT zur FORDERUNG der WISSENSCHAFTEN e.V., UNIVERSITY OF ROCHESTERInventors: Jane Sottile, Inaam Nakchbandi, Burns C. Blaxall
-
Publication number: 20130184212Abstract: The present application provides fibronectin based scaffold proteins associated with improved stability. The application also relates to stable formulations of fibronectin based scaffold proteins and the use thereof in diagnostic, research and therapeutic applications. The application further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising such polynucleotides.Type: ApplicationFiled: May 26, 2011Publication date: July 18, 2013Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Ray Camphausen, John O'Loughlin, Bernice Yeung, Yihong Zhang
-
Patent number: 8476010Abstract: A sterile pharmaceutical composition for parenteral administration of propofol, said composition comprising propofol, optionally albumin, and less than about 10% by weight solvent for propofol, wherein said composition is stored in a container having a closure wherein said closure is inert to propofol.Type: GrantFiled: July 10, 2003Date of Patent: July 2, 2013Assignee: APP Pharmaceuticals LLCInventors: Neil P. Desai, Andrew Yang, Sherry Xiaopei Ci
-
Patent number: 8470332Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.Type: GrantFiled: November 21, 2007Date of Patent: June 25, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Ray Camphausen, David Fabrizio, Martin C. Wright, Patrick Gage, John Mendlein
-
Publication number: 20130156819Abstract: The present invention relates to peptides or fragments thereof, which peptides bind to mesenchymal stem cells. The present invention also relates to a method for identifying, isolating, specifically selecting and/or enriching mesenchymal stem cells, wherein the peptides, or fragments thereof, are employed for specifically binding to the mesenchymal stem cells. Also, the present invention relates to the use of the peptides of the invention, or fragments thereof, and of the mesenchymal stem cells isolated with the peptides of the invention, or fragments thereof, for treating, injuries and/or degenerated bone, cartilage or tissues.Type: ApplicationFiled: December 5, 2012Publication date: June 20, 2013Applicants: Baden-Württemberg Stiftung gGmbH, Eberhard-Karls-Universit°t Tübingen Universit°tsklinikumInventors: Eberhard-Karls-Universit°t Tübingen Universit°tskl, Baden-Württemberg Stiftung gGmbH
-
Publication number: 20130157948Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.Type: ApplicationFiled: December 3, 2012Publication date: June 20, 2013Applicant: BRISTOL-MYERS SQUIBB COMPANYInventor: Bristol-Myers Squibb Company
-
Publication number: 20130108700Abstract: The present invention provides compositions and methods useful in the treatment of wounds, particularly in reducing or preventing scar formation, particularly hypertrophic scar or keloid formation. The invention thus further provides methods of treatment, including methods useful in hypertrophic scar or keloid revision as well as prophylactic, scar inhibiting methods.Type: ApplicationFiled: November 1, 2012Publication date: May 2, 2013Applicant: Halscion, Inc.Inventor: Halscion, Inc.
-
Publication number: 20130096058Abstract: The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increased stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer.Type: ApplicationFiled: April 12, 2011Publication date: April 18, 2013Applicant: MedImmune, LLCInventors: Manuel Baca, Thomas Thisted, Jeffrey Swers, David Tice
-
Publication number: 20130089548Abstract: A method for inducing apoptosis of tumoral cells in a patient having cancer cells bearing Cell-adhesion molecule-related/Downregulated by Oncogenes (CDO) receptors and expressing Sonic Hedgehog (SHH), including administering to the patient an effective amount of an agonist of CDO's apoptotic function, wherein the agonist is selected from the group consisting of a CDO fragment, a fusion protein comprising a CDO fragment, an antibody against SHH, and an siRNA which is capable of inhibiting SHH expression, and related CDO fragments, fusion proteins comprising a CDO fragment, antibodies against SHH, and siRNAs which are capable of inhibiting SHH expression.Type: ApplicationFiled: March 23, 2011Publication date: April 11, 2013Applicant: NETRIS PHARMAInventors: Patrick Mehlen, Celine Delloye-Bourgeois, Agnes Bernet, Jean Guy Delcros, Pascale Nony
-
Publication number: 20130079280Abstract: The present invention provides fibronectin type III (Fn3)-based multimeric scaffolds that specifically bind to one or more specific target antigen. The invention further provides bispecific Fn3-derived binding molecules that bind to two or more target antigens simultaneously, fusions, conjugates, and methods to increase the stability of Fn3-based binding molecules. Furthermore, the present invention is related to a prophylactic, therapeutic or diagnostic agent, which contains Fn3-based multimeric scaffolds.Type: ApplicationFiled: April 12, 2011Publication date: March 28, 2013Applicant: Medlmmune, LLCInventors: Manuel Baca, Thomas Thisted, Jeffrey Swers
-
Patent number: 8394924Abstract: The present invention features engineered proteins that include a first polypeptide that specifically binds a first target (e.g., a cellular target, such as a cell-surface antigen) and a second polypeptide that selectively binds an activating FcR.Type: GrantFiled: October 23, 2009Date of Patent: March 12, 2013Assignee: Massachusetts Institute of TechnologyInventors: K. Dane Wittrup, Shanshan Wu Howland
-
Publication number: 20130012436Abstract: The present invention relates to fibronectin based scaffold domain protein that bind interleukin 23 (IL-23), specifically the p19 subunit of IL-23. The invention also relates to the use of the innovative proteins in therapeutic applications to treat autoimmune diseases. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: ApplicationFiled: February 16, 2011Publication date: January 10, 2013Inventors: Ruchira Dasgupta, Alex Bush, Lumelle Schneeweis, Linda Engle
-
Publication number: 20130004543Abstract: Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, EGF, bFGF, or KGF and fibronectin, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of fibronectin. These protein complexes include synthetic proteins where the growth factor and fibronectin sequences are joined by a linker sequence. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement, skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, the invention provides inhibition of cancer cell metastasis, particularly in relation to breast cancer.Type: ApplicationFiled: November 30, 2010Publication date: January 3, 2013Applicant: Queensland University of TechnologyInventors: Zee Upton, Derek Van Lonkhuyzen
-
Patent number: 8343501Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.Type: GrantFiled: November 24, 2009Date of Patent: January 1, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Stuart Emanuel, Linda Engle, Ray Camphausen, Martin C. Wright, Ginger Chao, Marco Gottardis, Joan Carboni
-
Patent number: 8324362Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.Type: GrantFiled: May 26, 2010Date of Patent: December 4, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
-
Publication number: 20120301393Abstract: The present invention refers to novel recombinant proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B). Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component.Type: ApplicationFiled: December 14, 2010Publication date: November 29, 2012Inventors: Arnd Steuernagel, Erik Fiedler, Markus Fiedler, Anja Kunert, Joerg Nerkamp, Thomas Goettler, Manja Gloser, Ilka Haenssgen